512 related articles for article (PubMed ID: 16266320)
21. Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics?
Galili U
Glycobiology; 2016 Nov; 26(11):1140-1150. PubMed ID: 27567275
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody.
Henion TR; Gerhard W; Anaraki F; Galili U
Vaccine; 1997 Aug; 15(11):1174-82. PubMed ID: 9286041
[TBL] [Abstract][Full Text] [Related]
23. Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA.
Deriy L; Chen ZC; Gao GP; Galili U
Glycobiology; 2002 Feb; 12(2):135-44. PubMed ID: 11886847
[TBL] [Abstract][Full Text] [Related]
24. L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies.
Chen W; Gu L; Zhang W; Motari E; Cai L; Styslinger TJ; Wang PG
ACS Chem Biol; 2011 Feb; 6(2):185-91. PubMed ID: 21043478
[TBL] [Abstract][Full Text] [Related]
25. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
Galili U
Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
[TBL] [Abstract][Full Text] [Related]
26. Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene.
Ogawa H; Yin DP; Galili U
Gene Ther; 2004 Feb; 11(3):292-301. PubMed ID: 14737089
[TBL] [Abstract][Full Text] [Related]
27. Conversion of tumors into autologous vaccines by intratumoral injection of α-Gal glycolipids that induce anti-Gal/α-Gal epitope interaction.
Galili U
Clin Dev Immunol; 2011; 2011():134020. PubMed ID: 22162709
[TBL] [Abstract][Full Text] [Related]
28. Natural protection from zoonosis by alpha-gal epitopes on virus particles in xenotransmission.
Kim NY; Jung WW; Oh YK; Chun T; Park HY; Lee HT; Han IK; Yang JM; Kim YB
Xenotransplantation; 2007 Mar; 14(2):104-11. PubMed ID: 17381684
[TBL] [Abstract][Full Text] [Related]
29. Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation.
Tanemura M; Yin D; Chong AS; Galili U
J Clin Invest; 2000 Feb; 105(3):301-10. PubMed ID: 10675356
[TBL] [Abstract][Full Text] [Related]
30. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.
Abdel-Motal U; Wang S; Lu S; Wigglesworth K; Galili U
J Virol; 2006 Jul; 80(14):6943-51. PubMed ID: 16809300
[TBL] [Abstract][Full Text] [Related]
31. Elimination of anti-Gal B cells by alpha-Gal ricin1.
Tanemura M; Ogawa H; Yin DP; Chen ZC; DiSesa VJ; Galili U
Transplantation; 2002 Jun; 73(12):1859-68. PubMed ID: 12131678
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy to inhibit xenoantibody production using lentiviral vectors in non-human primates.
Fischer-Lougheed JY; Tarantal AF; Shulkin I; Mitsuhashi N; Kohn DB; Lee CC; Kearns-Jonker M
Gene Ther; 2007 Jan; 14(1):49-57. PubMed ID: 16886002
[TBL] [Abstract][Full Text] [Related]
33. Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase.
LaTemple DC; Galili U
Xenotransplantation; 1998 Aug; 5(3):191-6. PubMed ID: 9741457
[TBL] [Abstract][Full Text] [Related]
34. In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids.
Galili U; Albertini MR; Sondel PM; Wigglesworth K; Sullivan M; Whalen GF
Cancers (Basel); 2010; 2(2):773-93. PubMed ID: 23087817
[TBL] [Abstract][Full Text] [Related]
35. Avoiding detrimental human immune response against Mammalian extracellular matrix implants.
Galili U
Tissue Eng Part B Rev; 2015 Apr; 21(2):231-41. PubMed ID: 25315097
[TBL] [Abstract][Full Text] [Related]
36. Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Galili U; Chen ZC; Manches O; Plumas J; Preisler H
J Hematother Stem Cell Res; 2001 Aug; 10(4):501-11. PubMed ID: 11522233
[TBL] [Abstract][Full Text] [Related]
37. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
39. [Why humans and Catarrhini lack the Galalpha1-3Gal epitope, related to xenograft rejection?].
Suchanowska A; Czerwiński M
Postepy Hig Med Dosw (Online); 2009 Jun; 63():250-7. PubMed ID: 19502686
[TBL] [Abstract][Full Text] [Related]
40. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells.
Galili U; Shohet SB; Kobrin E; Stults CL; Macher BA
J Biol Chem; 1988 Nov; 263(33):17755-62. PubMed ID: 2460463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
